Cited by 98Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsCancer-related Molecular Pathways

MDM2 and CDK4 Immunohistochemical Coexpression in High-grade Osteosarcoma: Correlation With a Dedifferentiated Subtype

Yoshida, Akihiko, Ushiku, Tetsuo, Motoi, Toru, Beppu, Yasuo, Fukayama, Masashi, Tsuda, Hitoshi, Shibata, Tatsuhiro·2012·American Journal of Surgical Pathology

Abstract

Low-grade osteosarcomas comprise a distinct subset of osteosarcomas. They may occasionally dedifferentiate into high-grade tumors, typically in the form of high-grade osteosarcoma, which are histologically indistinguishable from conventional osteosarcomas. MDM2 and CDK4 are often amplified in low-grade osteosarcomas and their dedifferentiated counterparts, and the encoded proteins are accordingly overexpressed. As MDM2/CDK4 expression was reportedly rare in conventional osteosarcoma, we hypothesized that these markers may help separate dedifferentiated osteosarcoma from the conventional type. To test this, we performed MDM2 and CDK4 immunohistochemistry on 81 primary and 26 recurrent/metastatic high-grade osteosarcomas and correlated these data with the histology of the primary resection material, with particular attention to the potential presence of any coexisting low-grade osteosarcomatous components. MDM2 and CDK4 coexpression was identified in 7 cases, and on careful histologic review 6 of them were discovered to contain foci of coexisting low-grade elements. One case was a known dedifferentiated parosteal osteosarcoma, and the remaining 5 cases were newly identified dedifferentiated osteosarcomas in which the limited low-grade components were originally unrecognized. An additional 11 cases expressed either marker alone, whereas the remaining 89 cases were negative for both markers; no resection material from these 100 cases presented with a low-grade component. MDM2/CDK4 gene amplification status, determined by quantitative polymerase chain reaction in selected cases, was largely concordant with immunoexpression. Our data suggest that MDM2 and CDK4 coexpression in high-grade osteosarcomas is sensitive and specific to those that progressed from low-grade osteosarcomas, and immunohistochemistry may help identify this dedifferentiated subgroup to facilitate accurate subclassification.

Integrity signals

Registry

Crossref · 10.1097/pas.0b013e31824230d0

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

2 of the 31 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Yoshida, A., Ushiku, T., Motoi, T., Beppu, Y., Fukayama, M., Tsuda, H., & Shibata, T.
Affiliations
  • National Cancer Center Hospital (JP)
  • The University of Tokyo (JP)
  • Tokyo Metropolitan Komagome Hospital (JP)
  • National Cancer Center Research Institute (JP)
Corresponding author
  • Yoshida, Akihiko
  • Tsuda, Hitoshi
  • Shibata, Tatsuhiro
Venue
American Journal of Surgical Pathology
Published
2012-03
Volume
36
Issue
3
Pages
423-431
ISSN
0147-5185 (ISSN-L)
OpenAlex
W2032358116
Cited by
98
References
31
Citations by year
2026: 1 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 9 · 2020: 5 · 2019: 7 · 2018: 10 · 2017: 5 · 2016: 12 · 2015: 9 · 2014: 9 · 2013: 3
FWCI
5.41
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Surgical Pathology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (21590386)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
high-grade osteosarcoma, low-grade osteosarcoma, MDM2, CDK4, gene amplification, tumor subclassification, parosteal osteosarcoma, immunohistochemical markers
MeSH terms
Adolescent, Adult, Aged, Biopsy, Bone Neoplasms, Child, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Recurrence, Local, Predictive Value of Tests, Prognosis, Retrospective Studies, Osteosarcoma, Biomarkers, Tumor, Cyclin-Dependent Kinase 4, Proto-Oncogene Proteins c-mdm2, Cell Dedifferentiation, Young Adult, Neoplasm Grading, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review